Enveda Raises $311 Million to Push AI-Discovered Natural Medicines Into Clinical Trials

Most drug discovery still starts with a chemist screening synthetic compound libraries one target at a time. Enveda is betting that nature already solved much of that problem, and that AI is what finally makes its chemistry legible at scale.

Enveda Biosciences closed a $311 million Series E round, led by Catalio Capital Management with participation from Iconiq, valuing the AI-native biotech at $2 billion, double its valuation from twelve months earlier. The round brings Enveda's total capital raised since inception to more than $845 million. The clinical-stage company uses PRISM, its AI-native platform for identifying biologically active molecules found in nature, and plans to use the new funding to advance lead programs ENV-294 and ENV-308 into later-stage clinical trials, move ENV-6946 through mid-stage development, and bring additional programs for inflammatory and metabolic diseases into clinical testing.

Why Nature-Derived Chemistry Needed AI to Become Investable at Scale

Natural compounds have always offered a vast and chemically diverse starting point for drug discovery, but the field has historically struggled to systematically identify which of the millions of molecules found in plants, fungi and other natural sources are worth pursuing. Enveda's AI platform is built specifically to make that search tractable, mapping biological activity against its library of natural compounds the way a computational chemist would screen a synthetic library, a reframing that turns what used to be a slow, largely serendipitous discipline into something closer to a systematic pipeline.

Why a Doubled Valuation Followed Real Clinical Readouts

Enveda's valuation doubling over twelve months tracks closely with the company's reported Phase 1b results for ENV-294, which reduced eczema severity by an average of 85% after 42 days in patients being treated for atopic dermatitis. A biotech's valuation re-rating that closely following disclosed clinical data, rather than preceding it, is the pattern investors generally want to see: capital following evidence rather than anticipating it, a distinction that matters considerably in a sector where hype has historically outpaced clinical validation.

What This Means for Founders

For founders building AI-native biotech or any company applying machine learning to a historically slow, serendipity-driven discipline, Enveda's trajectory, raising a large round specifically after disclosing real clinical data rather than purely on platform promise, is a useful model for sequencing a capital-raising strategy around genuine proof points. Founders in adjacent categories should also note Enveda's total raised to date, more than $845 million across its history, as a reminder that AI-native biotech at the clinical stage remains one of the most capital-intensive categories to compete in, requiring investors with the balance sheet and patience to fund multiple rounds before any single program reaches approval.

Browse the biotech investor directory and AI and machine learning investor directory for more active funds in AI-native drug discovery, read the baseline mechanics of a post-money valuation and how it compounds across a company's funding history if the concept is new, or explore active capital on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai